Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors
Oncology
Prevalence
48.0 / 100K
Incidence
15.0 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| AB521 | EXELIXIS, INC. (EXEL) |
Frequently asked questions
How many drugs are in development for Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors?
BioSniper tracks 1 drug in development for Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors across 1 company.
How many clinical trials target Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors?
There are 1 clinical trial targeting Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors tracked by BioSniper.
What is the prevalence of Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors?
The estimated prevalence of Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors is approximately 48.0 per 100,000 population.
Deep-dive into Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis